ABSTRACT
In dogs injected intravenously with 400mg/m(2) cyclophosphamide (CPA), the peripheral neutrophil count decreased to less than 1000 cells/µL in 5-9 days. Treatment with purified recombinant canine granulocyte colony-stimulating factor (rcG-CSF), produced by brevibacillus expression system, at the nadir of the granulocyte count accelerated recovery from the CPA-induced neutropenia by 1-3 days. Therapeutic administration of rcG-CSF at doses of 2.5-10 µg/kg did not show any significant difference on the severity of neutropenia (the period that granulocyte counts were less than 2000 cells/µL). Administration of 2.5 µg/kg rcG-CSF 3 times per day 2-4 days or 3-5 days after CPA treatment not only accelerated recovery but also decreased the severity of neutropenia. No clinical signs of the rcG-CSF were observed. These results showed that the rcG-CSF is effective for treatment of neutropenia in dogs.
Subject(s)
Cyclophosphamide/adverse effects , Dogs/blood , Granulocyte Colony-Stimulating Factor/pharmacology , Neutropenia/chemically induced , Neutropenia/drug therapy , Animals , Leukocyte Count/veterinaryABSTRACT
Most animal cells that are exposed to interferon (IFN) experience an increase in the activity of 2', 5'-oligoadenylate synthetase (OAS), which is an important effector of IFN's antiviral action. OAS activity has been widely used in clinical chemistry as an indicator of IFN activity. In this study, we found that OAS activity in canine serum is 46.0 +/- 40.4 nmol/dl/hr, which is 10- to 100-fold higher than in other animals such as the cat (1.9 +/- 2.1), rabbit (4.0 +/- 1.1), and guinea pig (0.3 +/- 0.6). The canine OAS protein was detected by Western blotting using a 68M-10 monoclonal anti-murine OAS antibody, and was found to be composed of at least three distinct molecular species of p40 class OAS. Among these, the 40 and 42 kDa components were determined to be the major species in serum and fibroblast cell lines, respectively.
